AAV8-SIRT3

AAV8-SIRT3 has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 13, 2026: “Raising an immune-cell protein eased liver injury in aged mice”.

Intervention

1 paper studies it1 findingUpdated Oct 26, 2026

1 new paper in 30 daysSee all 1 papers on AAV8-SIRT3

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

1 lab in 1 country

Animals1

What did studies of AAV8-SIRT3 find?

Studies of AAV8-SIRT3 measured one outcome, hepatic ischemia reperfusion injury.

Hepatic ischemia reperfusion injury

downin mice1

1 study

AAV8-SIRT3 decreases hepatic ischemia reperfusion injury in mice (murine HIRI model).
“SIRT3 overexpression in liver macrophages also alleviated HIRI of aged mice.”
Animalsmurine HIRI modeladeno-associated virus serotype 8liver macrophage
Raising an immune-cell protein eased liver injury in aged mice
Hepatobiliary & pancreatic diseases international : HBPD INTOct 26, 2026

More on Hepatic ischemia reperfusion injury

Latest

1 paper in 12 months

Hepatobiliary & Pancreatic Diseases InternationalNov 13

Raising an immune-cell protein eased liver injury in aged mice

In experiments, aged mice had less of the protein and more injury than young mice after liver blood supply was interrupted and restored.In experiments, aged mice had less of the protein and more injury than young mice after liver blood supply was interrupted and restored.

Mouse studyBlood and immune system

Paper